<DOC>
	<DOCNO>NCT01311713</DOCNO>
	<brief_summary>CEP-9722 inhibitor poly-adenosine diphosphate ( ADP ) ribose polymerase -1 -2 ( PARP ) . The primary purpose study ( Part 1 ) determine maximum tolerate dose ( MTD ) CEP-9722 administered daily patient advance metastatic solid tumor , ( Part 2 ) evaluate safety tolerability dose , investigate whether CEP-9722 antitumor activity single agent .</brief_summary>
	<brief_title>Study Determine Maximum Tolerated Dose PARP Inhibitor CEP-9722 Patients With Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Poly ( ADP-ribose ) Polymerase Inhibitors</mesh_term>
	<criteria>The patient histologically confirm , locally advanced metastatic solid tumor consider incurable unresponsive standard therapy . The patient disease progression follow least 1 prior standard chemotherapy regimen . The patient man woman least 18 year age . The patient European Cooperative Oncology Group ( ECOG ) performance status 0 , 1 , 2 . The patient life expectancy 12 week . The patient adequate hematologic function evidence : absolute neutrophil cell ( ANC ) count 1.5 x109/L hemoglobin 10 g/dL platelet 100 x 109/L The patient adequate hepatic function evidence : total bilirubin 1.5 time upper limit normal ( ULN ) less , unless secondary Gilbert 's disease ( Gilbert 's disease must document , bilirubin must 3 time ULN less . ) alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) , alkaline phosphatase 2.5 time ULN less The patient adequate renal function define creatinine le 1.5 time ULN le . The patient must take precaution become pregnant produce offspring . Women must nonchildbearing potential ( surgically sterile postmenopausal least 12 month , confirm folliclestimulating hormone [ FSH ] &gt; 40 IU/L ) agree use medically accept method contraception duration study 90 day treatment . Men must surgically sterile agree use medically accept method contraception duration study 90 day treatment . Acceptable method contraception include abstinence , barrier method spermicide ( exclude cervical cap sponge ) , intrauterine device ( IUD ) , steroidal contraceptive ( oral , transdermal , implanted , inject ) conjunction barrier method . Written inform consent obtain . In Part 2 : In addition criterion , patient document deficiency DNA repair pathway , BRCA1/2 , prostate , breast , gastric cancer ability provide fresh archived tumor specimen . Other malignancy , patient serious uncontrolled surgical , medical , psychiatric history could pose unacceptable health risk patient , prevent compliance study procedure , compromise study integrity , include , limited following : 1. recent history cardiac ischemic disease ( acute myocardial infarction within 6 month , unstable angina ) 2. cardiac arrhythmia uncontrolled require medication 3. recent transient ischemic attack stroke ( within 6 month ) residual dysfunction stroke 4. history seizure disorder ( part 1 ) 5. clinically significant pulmonary disease ( eg , fibrosis chest xray significant dyspnea assess investigator ) 6. poorly control hypertension ( systolic &gt; 140 mm Hg diastolic &gt; 90 mm Hg ) 7. uncontrolled active infection within past 7 day 8. poorly control diabetes mellitus assess investigator 9. recent major surgery ( within 4 week prior study day 1 ) minor surgery ( within 2 week prior study day 1 ) The patient previously receive PARP inhibitor . The patient receive antitumor therapy investigational agent within 4 week ( exception LHRH therapy patient prostate cancer ) nitrosourea therapy within 6 week . The patient clinically symptomatic brain metastasis require treatment brain metastasis within 4 week ( stable sequela acceptable treatment complete ) . The patient residual adverse event great grade 1 severity prior radiotherapy chemotherapy agent . The patient know immunodeficiency virus ( HIV ) infection , acute chronic hepatitis B infection , hepatitis C infection . The patient pregnant breastfeed woman . ( Any woman become pregnant study withdrawn study . ) The patient medical surgical gastrointestinal history would interfere absorption study drug . The patient require treatment proton pump inhibitor H2 antagonist take proton pump inhibitor H2 antagonist within 4 day CEP9722 administration . The patient risk factor Torsades de Pointes follow : history Long QT syndrome unexplained syncope history congestive heart failure ( New York Heart Association class III IV ) concomitant treatment medication know prolong QT/QTc interval QTc great 450 msec screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>cancer</keyword>
	<keyword>tumor</keyword>
	<keyword>PARP</keyword>
</DOC>